Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
NCT03601819Phase 1Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- May 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pacritinib in T-cell lymphoma, chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia (WM) and 3 more, sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Rate of dose limiting toxicities at 28 days. Started May 2019; status: terminated.
02
Drugs
pacritinib
03
Conditions
T-cell lymphomachronic lymphocytic leukemia (CLL)Waldenstrom macroglobulinemia (WM)Lymphoplasmacytic Lymphoma (LPL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03601819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03601819.